Caspases in COVID-19 Disease and Sequela and the Therapeutic Potential of Caspase Inhibitors
Abstract Currently, there is no effective vaccine and only one FDA approved early-stage therapy against SARS-CoV-2 infection as an indication to prevent disease progression. Cellular caspases play a role in the pathophysiology of a number of disorders that the co-morbid conditions seen in severe COVID-19 disease. In this study, we assessed transcriptional states of caspases in blood cells from COVID-19 patients. Gene expression levels of select caspases were increased inin vitroSARS-CoV-2 infection models and single cell RNA-Seq data of blood from COVID-19 patients showed a distinct caspase expression in T cells, neutrophils, and dendritic cells. Flow cytometric evaluation of CD4 T cells showed up-regulation of caspase-1 in hospitalized COVID-19 patients compared to unexposed controls. Convalescent COVID-19 patients with lingering symptoms (“long haulers”) showed persistent up-regulation of caspase-1 in CD4 T cells that was attenuatedex vivofollowing co-culture with a select pan-caspase inhibitor. Further, we observed elevated caspase-3 levels in red blood cells from COVID-19 patients compared to controls that were responsive to caspase inhibition. Our results expose an exuberant caspase response in COVID-19 that may facilitate immune-related pathological processes leading to severe outcomes. Pan-caspase inhibition could emerge as a therapeutic strategy to ameliorate or prevent severe COVID-19 outcomes..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Plassmeyer, Matthew [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2020.11.02.20223636 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019257767 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019257767 | ||
| 003 | DE-627 | ||
| 005 | 20240425104756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201106s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.11.02.20223636 |2 doi | |
| 035 | |a (DE-627)XBI019257767 | ||
| 035 | |a (biorXiv)10.1101/2020.11.02.20223636 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Plassmeyer, Matthew |e verfasserin |0 (orcid)0000-0001-8068-2125 |4 aut | |
| 245 | 1 | 0 | |a Caspases in COVID-19 Disease and Sequela and the Therapeutic Potential of Caspase Inhibitors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Currently, there is no effective vaccine and only one FDA approved early-stage therapy against SARS-CoV-2 infection as an indication to prevent disease progression. Cellular caspases play a role in the pathophysiology of a number of disorders that the co-morbid conditions seen in severe COVID-19 disease. In this study, we assessed transcriptional states of caspases in blood cells from COVID-19 patients. Gene expression levels of select caspases were increased inin vitroSARS-CoV-2 infection models and single cell RNA-Seq data of blood from COVID-19 patients showed a distinct caspase expression in T cells, neutrophils, and dendritic cells. Flow cytometric evaluation of CD4 T cells showed up-regulation of caspase-1 in hospitalized COVID-19 patients compared to unexposed controls. Convalescent COVID-19 patients with lingering symptoms (“long haulers”) showed persistent up-regulation of caspase-1 in CD4 T cells that was attenuatedex vivofollowing co-culture with a select pan-caspase inhibitor. Further, we observed elevated caspase-3 levels in red blood cells from COVID-19 patients compared to controls that were responsive to caspase inhibition. Our results expose an exuberant caspase response in COVID-19 that may facilitate immune-related pathological processes leading to severe outcomes. Pan-caspase inhibition could emerge as a therapeutic strategy to ameliorate or prevent severe COVID-19 outcomes. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Alpan, Oral |e verfasserin |0 (orcid)0000-0001-7467-8541 |4 aut | |
| 700 | 1 | |a Corley, Michael J. |e verfasserin |0 (orcid)0000-0002-2348-5536 |4 aut | |
| 700 | 1 | |a Lillard, Kimberleigh |e verfasserin |4 aut | |
| 700 | 1 | |a Coatney, Paige |e verfasserin |4 aut | |
| 700 | 1 | |a Vaziri, Tina |e verfasserin |4 aut | |
| 700 | 1 | |a Michalsky, Suzan |e verfasserin |4 aut | |
| 700 | 1 | |a Premeaux, Thomas A. |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Alina P.S. |e verfasserin |4 aut | |
| 700 | 1 | |a Bukhari, Zaheer |e verfasserin |4 aut | |
| 700 | 1 | |a Yueng, Stephen T. |e verfasserin |4 aut | |
| 700 | 1 | |a Evering, Teresa H |e verfasserin |4 aut | |
| 700 | 1 | |a Naughton, Gail |e verfasserin |4 aut | |
| 700 | 1 | |a Latterich, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Mudd, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Spada, Alfred |e verfasserin |4 aut | |
| 700 | 1 | |a Rindone, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Loizou, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Ndhlovu, Lishomwa C. |e verfasserin |0 (orcid)0000-0001-5427-4187 |4 aut | |
| 700 | 1 | |a Gupta, Raavi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1111/all.14907 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.11.02.20223636 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||